Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1636gxl
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Sep 29	The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST
NEWS 3	Oct 27	New Extraction Code PAX now available in Derwent Files
NEWS 4	Oct 27	SET ABBREVIATIONS and SET PLURALS extended in Derwent World Patents Index files
NEWS 5	Oct 27	Patent Assignee Code Dictionary now available in Derwent Patent Files
NEWS 6	Oct 27	Plasdoc Key Serials Dictionary and Echoing added to Derwent Subscriber Files WPIDS and WPIX
NEWS 7	Nov 29	Derwent announces further increase in updates for DWPI
NEWS 8	Dec 5	French Multi-Disciplinary Database PASCAL Now on STN
NEWS 9	Dec 5	Trademarks on STN - New DEMAS and EUMAS Files
NEWS 10	Dec 15	2001 STN Pricing
NEWS 11	Dec 17	Merged CEABA-VTB for chemical engineering and biotechnology
NEWS 12	Dec 17	Corrosion Abstracts on STN
NEWS 13	Dec 17	SYNTHLINE from Prous Science now available on STN
NEWS 14	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 15	Jan 05	AIDSLINE is being removed from STN

NEWS EXPRESS	FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 10 JAN 2001 HIGHEST RN 313467-31-1
DICTIONARY FILE UPDATES: 10 JAN 2001 HIGHEST RN 313467-31-1

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> S TCL-1

```
            22 TCL
      10733823 1
L1           1 TCL-1
                 (TCL(W)1)
```

=> D L1 SQD CN SQL SEQ

'CN' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'SQL' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'
'SEQ' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

```
REG     - RN
SAM     - Index Name, MF, and structure - no RN
FIDE    - All substance data, except sequence data
IDE     - FIDE, but only 50 names
SQIDE   - IDE, plus sequence data
SQIDE3  - Same as SQIDE, but 3-letter amino acid codes are used
SQD     - Protein sequence data, includes RN
SQD3    - Same as SQD, but 3-letter amino acid codes are used
SQN     - Protein sequence name information, includes RN
```

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

```
ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
```

SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
ENTER DISPLAY FORMAT (IDE):CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
CN **TCL 1 (9CI)** (CA INDEX NAME)

=> D L1 SEQ

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

=> D SEQ L1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

=> D HIS

(FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001)

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001
L1 1 S TCL-1

=> TCL-1

TCL-1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> S TCL-1

22 TCL
10733823 1
L2 1 TCL-1
(TCL(W)1)

=> D SEQ3 L2 1

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

=> FILE USPAT CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.87	19.02

FILE 'USPATFULL' ENTERED AT 19:04:57 ON 11 JAN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CAPLUS' ENTERED AT 19:04:57 ON 11 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> S L2

L3 1 L2

=> D IBIB AB L3

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:574176 CAPLUS
DOCUMENT NUMBER: 133:254659
TITLE: Research of chloride removal catalyst for liquid phase
AUTHOR(S): Nagai, Akihisa; Inoue, Mitsuhiro; Watanabe, Shinichi; Fukuda, Kazuyuki
CORPORATE SOURCE: Lab. Res. Sect., Taiyo Engineering Co., Ltd., Ehime, 799-2393, Japan
SOURCE: Aromatikkusu (2000), 52(3/4), 77-81
CODEN: AROMBO; ISSN: 0365-6187
PUBLISHER: Nippon Hokozoku Kogyokai
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB Chloride compds. in liq. hydrocarbons, esp. reformate made in Continuous Catalyst Regeneration (CCR) Platforming unit, cause equipments corrosion, deposit of NH4Cl, and other problems. To prevent these problems, chloride compds. are removed by various kinds of chloride removal materials in each plant. But the life of alumina type in chloride removal materials is very short due to small pick up capacity and polymn. of hydrocarbons. So we started a joint research of chloride removal catalyst for liq. phase with Catalysts and Chems. Inc., Far East (CCIFE). As the result, in Taiyo Oil Co., Ltd. the reformate chloride treater packed with C125-1-01E (ZnO type by CCIFE) was installed in August 1998 and has been operated with a good result for about one year. We further had worked cooperating with CCIFE to extend its life and commercialized new improved type of catalyst (TCL-1). TCL-1 will be packed and started operation in Taiyo oil Co., Ltd. and be made and on sales by CCIFE.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.62	22.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.59	-0.59

FILE 'REGISTRY' ENTERED AT 19:06:13 ON 11 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 10 JAN 2001 HIGHEST RN 313467-31-1
DICTIONARY FILE UPDATES: 10 JAN 2001 HIGHEST RN 313467-31-1

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> S AECPTLGEAVTD

L4 0 AECPTLGEAVTD

=> S MLLELLPD

L5 0 MLLELLPD

=> S AECPTLGEAVTD/SQSP

L6 2 AECPTLGEAVTD/SQSP

=> D CN SQL SEQ 1,2

L6 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2001 ACS
CN Protein (human clone pAL1.5 gene TCL1) (9CI) (CA INDEX NAME)
SQL 114

SEQ 1 MAECPTLGEA VTDHPDRLWA WEKFVYLDEK QHAWLPLTIE IKDRLQLRVL
========== ===
51 LRREDVVLGR PMTPTQIGPS LLPIMWQLYP DGRYRSSDSS FWRLVYHIKI
101 DGVEDMLLEL LPDD
HITS AT: 2-13

L6 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2001 ACS
CN Protein (human gene TCL1) (9CI) (CA INDEX NAME)
SQL 114

SEQ 1 MAECPTLGEA VTDHPDRLWA WEKFVYLDEK QHAWLPLTIE IKDRLQLRVL
========== ===
51 LRREDVVLGR SMTPTQIGPS LLPIMWQLYP DGRYRSSDSS FWRLVYHIKI
101 DGVEDMLLEL LPDD
HITS AT: 2-13

=> FILE CAPLUS USPAT

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.85	67.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.59

FILE 'CAPLUS' ENTERED AT 19:08:57 ON 11 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 19:08:57 ON 11 JAN 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> D HIS

(FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001)

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001
L1 1 S TCL-1
L2 1 S TCL-1

FILE 'USPATFULL, CAPLUS' ENTERED AT 19:04:57 ON 11 JAN 2001
L3 1 S L2

FILE 'REGISTRY' ENTERED AT 19:06:13 ON 11 JAN 2001
L4 0 S AECPTLGEAVTD
L5 0 S MLLELLPD
L6 2 S AECPTLGEAVTD/SQSP

FILE 'CAPLUS, USPATFULL' ENTERED AT 19:08:57 ON 11 JAN 2001

=> S L6

L7 4 L6

=> DUPLICATE REMOVE L7

DUPLICATE PREFERENCE IS 'CAPLUS, USPATFULL'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):N

PROCESSING COMPLETED FOR L7
L8 4 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> D IBIB AB L8

L8 ANSWER 1 OF 4 USPATFULL
ACCESSION NUMBER: 1999:146298 USPATFULL
TITLE: TCL-1 gene and protein and related methods and compositions
INVENTOR(S): Russo, Giandomenico, Rome, Italy
Croce, Carlo M., Philadelphia, PA, United States
PATENT ASSIGNEE(S): Thomas Jefferson University, Philadelphia, PA, United States (U.S. corporation)
Raggio-Italgene S.p.A., Rome, Italy (non-U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5985598	19991116	
APPLICATION INFO.:	US 1994-330272	19941027	(8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Degen, Nancy
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 18 Drawing Page(s)
LINE COUNT: 2606
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to nucleotide sequences of TCL-1 genes and
amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation. The present invention further relates to the use of TCL-1 genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with chromosomal abnormalities.

=> D IBIB AB L8 2-4

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:418015 CAPLUS
DOCUMENT NUMBER: 125:83713
TITLE: Cloning of cDNA and gene of human TCL-1 protein and use for diagnosis, prevention, and treatment of diseases
INVENTOR(S): Russo, Giandomenico; Croce, Carlo M.
PATENT ASSIGNEE(S): Thomas Jefferson University, USA; Raggio-Italgene, S.P.A.
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613514	A1	19960509	WO 1995-US13663	19951023
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5985598	A	19991116	US 1994-330272	19941027
AU 9540084	A1	19960523	AU 1995-40084	19951023
PRIORITY APPLN. INFO.:			US 1994-330272	19941027
			WO 1995-US13663	19951023

AB The present invention relates to nucleotide sequences of TCL-1 genes and amino acid sequences of their encoded proteins, as well as derivs. and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation and is mapped on chromosome 14q32.1. A PCR-based method using the nucleotides derived from TCL-1 gene for detecting the chromosome 14 abnormality such as t(14;14)(q11;q32) translocation or an inv(14)(q11;q32) inversion is described. The present invention further relates to the use of TCL-1 genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states assocd. with chromosomal abnormalities.

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:284843 CAPLUS
DOCUMENT NUMBER: 122:102843
TITLE: Identification of the TCL1 gene involved in T-cell malignancies
AUTHOR(S): Virgilio, Laura; Narducci, Maria Grazia; Isobe, Masaharu; Billips, Linda G.; Cooper, Max D.; Croce, Carlo M.; Russo, Giandomenico
CORPORATE SOURCE: Jefferson Cancer Cent., Jefferson Med. Coll., Philadelphia, PA, 19107, USA
SOURCE: Proc. Natl. Acad. Sci. U. S. A. (1994), 91(26), 12530-4
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The TCL1 locus on chromosome 14q32.1 is frequently involved in chromosomal translocations and inversions with one of the T-cell receptor loci in human T-cell leukemias and lymphomas. The chromosome 14 region translocated or rearranged involves .apprxeq.350 kb of DNA at chromosome band 14q32.1. Within this region the authors have identified a gene coding for a 1.3-kb transcript, expressed only in restricted subsets of cells within the lymphoid lineage and expressed at high levels in leukemic cells carrying a t(14;14)(q11;q32) chromosome translocation or an inv(14)(q11;q32) chromosome inversion. The cognate cDNA sequence reveals

an open reading frame of 342 nt encoding a protein of 14 kDa. The TCL1 gene sequence, which, to the authors' knowledge, shows no sequence homol. with other human genes, is preferentially expressed early in T- and B-lymphocyte differentiation.

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:272585 CAPLUS
DOCUMENT NUMBER: 122:78055
TITLE: Characterization and localization of the TCL-1 oncogene product
AUTHOR(S): Fu, Tie-bo; Virgilio, Laura; Narducci, Maria Grazia; Facchiano, Antonio; Ruso, Giandomenico; Croce, Carlo M.
CORPORATE SOURCE: Jefferson Cancer Institute and Jefferson Cancer Center, Jefferson Medical College, Philadelphia, PA, 19107, USA
SOURCE: Cancer Res. (1994), 54(24), 6297-301
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The TCL-1 gene maps at chromosome 14q32.1 and its activated in T cell leukemias and lymphomas by either chromosome translocations or inversions that juxtapose the TCL-1 gene to the .alpha./.delta. or the .beta. locus of the T cell receptor. The open reading frame of the TCL-1 gene, coding for a protein of 114 amino acids, was expressed in bacteria and antisera were raised against it. The antibodies recognized the predicted TCL-1 Mr 14,000 protein product in cells expressing TCL-1 mRNA. Cell fractionation expts. indicated that the TCL-1 protein is present in the microsomal fraction. These results were confirmed by confocal microscopy. The TCL-1 protein has considerable sequence similarities to the product of the MTCP-1 gene on chromosome Xq28, which is involved in T cell lymphoproliferative diseases. Thus, TCL-1 may represent a member of a novel family of genes involved in lymphoid proliferation and/or survival and in T cell malignancies.

=> D HIS

(FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001)

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001
L1 1 S TCL-1
L2 1 S TCL-1

FILE 'USPATFULL, CAPLUS' ENTERED AT 19:04:57 ON 11 JAN 2001
L3 1 S L2

FILE 'REGISTRY' ENTERED AT 19:06:13 ON 11 JAN 2001
L4 0 S AECPTLGEAVTD
L5 0 S MLLELLPD
L6 2 S AECPTLGEAVTD/SQSP

FILE 'CAPLUS, USPATFULL' ENTERED AT 19:08:57 ON 11 JAN 2001
L7 4 S L6
L8 4 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

=> FILE MEDLINE EMBASE BIOSIS CAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.57	77.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

CA SUBSCRIBER PRICE [redacted] ENTRY -[redacted]6 SESSION -2.35

FILE 'MEDLINE' ENTERED AT 19:10:22 ON 11 JAN 2001

FILE 'EMBASE' ENTERED AT 19:10:22 ON 11 JAN 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 19:10:22 ON 11 JAN 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CAPLUS' ENTERED AT 19:10:22 ON 11 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

=> S L6

L9 3 L6

=> DUPLICATE REMOVE L9

PROCESSING COMPLETED FOR L9
L10 3 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)

=> D TI L10 1,2,3

L10 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2001 ACS
TI Cloning of cDNA and gene of human TCL-1 protein and use for diagnosis, prevention, and treatment of diseases

L10 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2001 ACS
TI Identification of the TCL1 gene involved in T-cell malignancies

L10 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2001 ACS
TI Characterization and localization of the TCL-1 oncogene product

=> S (CROCE, C?)/in,au

'IN' IS NOT A VALID FIELD CODE
'IN' IS NOT A VALID FIELD CODE
L11 2058 (CROCE, C?)/IN,AU

=> S (russo, g?)/in,au

'IN' IS NOT A VALID FIELD CODE
'IN' IS NOT A VALID FIELD CODE
L12 2131 (RUSSO, G?)/IN,AU

=> s l11 and l12

L13 89 L11 AND L12

=> s l13 and TCL-1

L14 11 L13 AND TCL-1

=> duplicate remove l14

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L14
L15 9 DUPLICATE REMOVE L14 (2 DUPLICATES REMOVED)

=> s l15 not l8

L16 8 L15 NOT L8

=> d ti l16 1-8

L16 ANSWER 1 OF 8 MEDLINE
TI TCL1 is overexpressed in patients affected by adult T-cell leukemias.

L16 ANSWER 2 OF 8 MEDLINE
TI Characterization and localization of the **TCL-1** oncogene product.

L16 ANSWER 3 OF 8 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
TI Deregulated expression of TCL1 causes T cell leukemia in mice.

L16 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
TI **TCL-1** gene and protein and related methods and compositions.

L16 ANSWER 5 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
TI Analysis of mice lacking the TCL1 gene suggests its involvement in female fertility and B and T cell survival.

L16 ANSWER 6 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
TI Cloning, mapping, and early expression of the murine **Tcl 1** (T-cell leukemia/lymphoma1) gene.

L16 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2001 ACS
TI Diagnostic probes and their use in detecting human chromosomal abnormalities

L16 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS
TI Role and significance of the T-cell leukemia/lymphoma (**TCL-1**) locus in hemopoietic malignancies

=> d ibib ab l16 1-8

L16 ANSWER 1 OF 8 MEDLINE
ACCESSION NUMBER: 1998069837 MEDLINE
DOCUMENT NUMBER: 98069837
TITLE: TCL1 is overexpressed in patients affected by adult T-cell leukemias.
AUTHOR: Narducci M G; Stoppacciaro A; Imada K; Uchiyama T; Virgilio
L; Lazzeri C; **Croce C M; Russo G**
CORPORATE SOURCE: Laboratory of Vascular Pathology, Roma, Italy.
CONTRACT NUMBER: CA 39860 (NCI)
SOURCE: CANCER RESEARCH, (1997 Dec 15) 57 (24) 5452-6.
Journal code: CNF. ISSN: 0008-5472.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Cancer Journals
ENTRY MONTH: 199803
ENTRY WEEK: 19980302
AB Among mature postthymic T-cell leukemias, adult T-cell leukemia (ATL) has characteristic clinicopathological entities. The association with the human T-cell leukemia/lymphotropic virus type I is one of the distinctive etiopathogenetic features of this disease. However, unlike other acute transforming retroviruses, the human T-cell leukemia/lymphotropic virus type I lacks an oncogene within its genome. Other human postthymic

leukemias, such as T-prolymphocytic leukemias, involve mostly the CD4 cellular subset and share many similarities to ATL (aggressive course, cutaneous involvement, CD4+, CD29+, CD45RA- phenotype, and alpha-naphthyl-acetate esterase positivity). A chromosomal rearrangement at 14q32.1, involved in translocations or inversions with either the alpha/delta locus [t(14;14)(q11;q32.1), inv14(q11;q32.1)], or the beta-chain locus of the T-cell receptor [t(7;14)(q35;q32.1)] is found. These rearrangements disregulate a gene, TCL1, located at the 14q32.1 region, that we show is physiologically expressed in CD4/CD8 double-negative thymocyte cells, but not in more differentiated CD4+ and CD8+ subpopulations. Here, using molecular and immunocytochemical analysis, we report that TCL1 is also overexpressed in 10 of 10 ATL specimens, indicating that this gene may play an important role in the pathogenesis of this disease.

L16 ANSWER 2 OF 8 MEDLINE
ACCESSION NUMBER: 95079394 MEDLINE
DOCUMENT NUMBER: 95079394
TITLE: Characterization and localization of the **TCL-1** oncogene product.
AUTHOR: Fu T B; Virgilio L; Narducci M G; Facchiano A; **Russo G; Croce C M**
CORPORATE SOURCE: Jefferson Cancer Institute, Jefferson Medical College, Philadelphia, Pennsylvania 19107.
SOURCE: CANCER RESEARCH, (1994 Dec 15) 54 (24) 6297-301.
Journal code: CNF. ISSN: 0008-5472.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Cancer Journals
ENTRY MONTH: 199503
AB The **TCL-1** gene maps at chromosome 14q32.1 and is activated in T cell leukemias and lymphomas by either chromosome translocations or inversions that juxtapose the **TCL-1** gene to the alpha/delta or the beta locus of the T cell receptor. The open reading frame of the **TCL-1** gene, coding for a protein of 114 amino acids, was expressed in bacteria and antisera were raised against it. The antibodies recognized the predicted **TCL-1** M(r) 14,000 protein product in cells expressing **TCL-1** mRNA. Cell fractionation experiments indicated that the **TCL-1** protein is present in the microsomal fraction. These results were confirmed by confocal microscopy. The **TCL-1** protein has considerable sequence similarities to the product of the MTCP-1 gene on chromosome Xq28, which is involved in T cell lympho-proliferative diseases. Thus, **TCL-1** may represent a member of a novel family of genes involved in lymphoid proliferation and/or survival and in T cell malignancies.

L16 ANSWER 3 OF 8 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1998125919 EMBASE
TITLE: Deregulated expression of TCL1 causes T cell leukemia in mice.
AUTHOR: Virgilio L.; Lazzeri C.; Bichi R.; Nibu K.-I.; Narducci M.G.; **Russo G.**; Rothstein J.L.; **Croce C.M.**
CORPORATE SOURCE: L. Virgilio, Kimmel Cancer Center, BLSB 1050, 233 South 10th Street, Philadelphia, PA 19107, United States. lvirgil@lac.jci.tju.edu
SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (31 Mar 1998) 95/7 (3885-3889).
Refs: 20
ISSN: 0027-8424 CODEN: PNASA6
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy

01 Cancer
02 Hematology
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The TCL1 oncogene on human chromosome 14q32.1 is involved in the development of T cell leukemia in humans. These leukemias are classified either as T prolymphocytic leukemias, which occur very late in life, or as T chronic lymphocytic leukemias, which often arise in patients with ataxia telangiectasia (AT) at a young age. The TCL1 oncogene is activated in these leukemias by juxtaposition to the .alpha. or .beta. locus of the T cell receptor, caused by chromosomal translocations t(14:14)(q11:q32), t(7:14)(q35:q32), or by inversions inv(14)(q11:q32). To show that transcriptional alteration of TCL1 is causally involved in the generation of T cell neoplasia we have generated transgenic mice that carry the TCL1 gene under the transcriptional control of the p56(lck) promoter element. The lck-TCL1 transgenic mice developed mature T cell leukemias after a long latency period. Younger mice presented preleukemic T cell expansions expressing TCL1, and leukemias developed only at an older age. The phenotype of the murine leukemias is CD4-CD8+, in contrast to human leukemias, which are predominantly CD4+CD8-. These studies demonstrate that transcriptional activation of the TCL1 protooncogene can cause malignant transformation oft lymphocytes, indicating the role of TCL1 in the initiation of malignant transformation in T prolymphocytic leukemias and T chronic lymphocytic leukemias.

L16 ANSWER 4 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 2000:279035 BIOSIS
DOCUMENT NUMBER: PREV200000279035
TITLE: **TCL-1** gene and protein and related methods and compositions.
AUTHOR(S): **Russo, Giandomenico (1); Croce, Carlo M.**
CORPORATE SOURCE: (1) Rome Italy
ASSIGNEE: Thomas Jefferson University, Philadelphia, PA, USA; Raggio-Italgene S.p.A.
PATENT INFORMATION: US 5985598 November 16, 1999
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Nov. 16, 1999) Vol. 1228, No. 3, pp. No pagination. e-file..
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
AB The present invention relates to nucleotide sequences of **TCL-1** genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The **TCL-1** gene sequence is preferentially expressed early in T and B lymphocyte differentiation. The present invention further relates to the use of **TCL-1** genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with chromosomal abnormalities.

L16 ANSWER 5 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 2000:227635 BIOSIS
DOCUMENT NUMBER: PREV200000227635
TITLE: Analysis of mice lacking the TCL1 gene suggests its involvement in female fertility and B and T cell survival.
AUTHOR(S): Narducci, Maria Grazia (1); Bevilacqua, Arturo; Kang, Sang-Moo; Lazzeri, Cristina; Bichi, Roberta; Minasi, Alessandra; Rothstein, Jay L.; Cooper, Max D.; Mangia, Franco; **Croce, Carlo M.; Russo, Giandomenico**
CORPORATE SOURCE: (1) IDI-IRCCS, Roma Italy
SOURCE: Proceedings of the American Association for Cancer Research

Annual Meeting, (March, 2000) No. 41 pp. 187-188.
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California,
USA April 01-05, 2000
ISSN: 0197-016X.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L16 ANSWER 6 OF 8 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1997:233179 BIOSIS
DOCUMENT NUMBER: PREV199799532382
TITLE: Cloning, mapping, and early expression of the murine **Tcl 1** (T-cell leukemia/lymphoma1) gene.
AUTHOR(S): **Russo, G. (1)**; Narducci, M. G.; Virgilio, L.; Engiles, L. B.; Billips, L.; Buchberg, A. M.; Facchiano, A.; Lazzeri, C.; Caprini, E.; **Croce, C. M.**; Rothstein, J.
CORPORATE SOURCE: (1) Ist. Dermopatico Immacolata-IRCCS, Rome Italy
SOURCE: Proceedings of the American Association for Cancer Research
Annual Meeting, (1997) Vol. 38, No. 0, pp. 446.
Meeting Info.: Eighty-eighth Annual Meeting of the American Association for Cancer Research San Diego, California, USA April 12-16, 1997
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; Abstract
LANGUAGE: English

L16 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1995:324656 CAPLUS
DOCUMENT NUMBER: 122:98781
TITLE: Diagnostic probes and their use in detecting human chromosomal abnormalities
INVENTOR(S): **Russo, Giandomenico**; Virgilio, Laura; Narducci, Maria Grazia; Carotenuto, Patrizia; Isobe, Masaharu; Croce, Carlo Maria
PATENT ASSIGNEE(S): Raggio-Italgene S.P.A., Italy
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9424308	A1	19941027	WO 1994-EP1183	19940415
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9466788	A1	19941108	AU 1994-66788	19940415
PRIORITY APPLN. INFO.:			GB 1993-7754	19930415
			WO 1994-EP1183	19940415

AB Several breakpoints assocd. with T-cell neoplasia have been mapped to the **tcl-1** locus. Accordingly, probes are made available that can be used for the diagnosis of a chromosomal abnormality occurring in the **tcl-1** locus, wherein each probe hybridizes with human chromosome 14q32.1 in an area of 300-450 kb spanning the AT581 and ALL320 breakpoints and spanned by the proximal probe 7-25 (centrometric) and the distal probe 21-2 (telomeric). Thus, a chromosome walking was started from two sites previously characterized: the breakpoint (ALL320) of a t(7;14)(q35;q32) chromosome translocation of a T-ALL patient with ataxia-telangiectasia (AT), and the breakpoint (MP) of a t(14;14)(q11;q32)

chromosome of another T cell leukemia patient with T. Primers and probes derived from sequences adjacent to the 2 breakpoints were used to screen a human genomic library prepd. in bacteriophage P1 cloning vector. A total of 12 clones were isolated, some of which were almost totally overlapping, to cover an area of 420 kb. Four other breakpoints were mapped within the **tcl-1** locus in patients with T-CLL, T-prolymphocytic leukemia, and T-cell lymphoma.

L16 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:652634 CAPLUS
DOCUMENT NUMBER: 121:252634
TITLE: Role and significance of the T-cell leukemia/lymphoma (**TCL-1**) locus in hemopoietic malignancies
AUTHOR(S): **Russo, G.**; Virgilio, L.; Narducci, M.G.; Carotenuto, P.; Frontani, M.; Isobe, M.; **Croce, C.M.**
CORPORATE SOURCE: Raggio-Italgene, Pomezia, 00040, Italy
SOURCE: Challenges Mod. Med. (1994), 2(Molecular Diagnosis and Monitoring of Leukaemia and Lymphoma), 29-36
CODEN: CHMME3
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 29 refs. including adult T-cell leukemia/lymphoma as a model of T-cell leukemogenesis, cytogenetic rearrangements at 14q32 obsd. in T-leukemia, and mol. aspects of chromosome translocations involving 14q32.

=> d his

(FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001)

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001
L1 1 S TCL-1
L2 1 S TCL-1

FILE 'USPATFULL, CAPLUS' ENTERED AT 19:04:57 ON 11 JAN 2001
L3 1 S L2

FILE 'REGISTRY' ENTERED AT 19:06:13 ON 11 JAN 2001
L4 0 S AECPTLGEAVTD
L5 0 S MLLELLPD
L6 2 S AECPTLGEAVTD/SQSP

FILE 'CAPLUS, USPATFULL' ENTERED AT 19:08:57 ON 11 JAN 2001
L7 4 S L6
L8 4 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 19:10:22 ON 11 JAN 2001
L9 3 S L6
L10 3 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)
L11 2058 S (CROCE, C?)/IN,AU
L12 2131 S (RUSSO, G?)/IN,AU
L13 89 S L11 AND L12
L14 11 S L13 AND TCL-1
L15 9 DUPLICATE REMOVE L14 (2 DUPLICATES REMOVED)
L16 8 S L15 NOT L8

=> s TCL-1

L17 82 TCL-1

=> S L16 NOT L16

L18 0 L16 NOT L16

=> S L17 NOT L16

L19 74 L17 NOT L16

=> DUPLICATE REMOVE L19

DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):N

PROCESSING COMPLETED FOR L19
L20 40 DUPLICATE REMOVE L19 (34 DUPLICATES REMOVED)

=> S L20 AND LEUKEMIA

L21 14 L20 AND LEUKEMIA

=> D TI L21 1-14

L21 ANSWER 1 OF 14 MEDLINE
TI The protooncogene TCL1 is an Akt kinase coactivator.

L21 ANSWER 2 OF 14 MEDLINE
TI ATM mutations in B-cell chronic lymphocytic **leukemia**.

L21 ANSWER 3 OF 14 MEDLINE
TI Transgenic mice for MTCP1 develop T-cell prolymphocytic **leukemia**

L21 ANSWER 4 OF 14 MEDLINE
TI Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic **leukemia** studied by fluorescence in situ hybridization.

L21 ANSWER 5 OF 14 MEDLINE
TI Crystal structure of MTCP-1: implications for role of **TCL-1** and MTCP-1 in T cell malignancies.

L21 ANSWER 6 OF 14 MEDLINE
TI Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2.

L21 ANSWER 7 OF 14 MEDLINE
TI Cytogenetics and oncogenes.

L21 ANSWER 8 OF 14 MEDLINE
TI Oncogenes in chronic lymphocytic **leukemia**.

L21 ANSWER 9 OF 14 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
TI Characterization and localization of the **TCL-1** oncogene product.

L21 ANSWER 10 OF 14 BIOSIS COPYRIGHT 2001 BIOSIS
TI Identification of the TCL1/MTCP1-like 1 (TML1) gene from the region next to the TCL1 locus.

L21 ANSWER 11 OF 14 BIOSIS COPYRIGHT 2001 BIOSIS
TI Role of TCL1 and ALL1 in human leukemias and development.

L21 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2001 ACS
TI Cloning of cDNA [redacted] gene of human **TCL-1** protein an[redacted]
use for diagnosis, prevention, and treatment of diseases

L21 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2001 ACS
TI MAGE-1 gene is expressed in T-cell **leukemia**

L21 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2001 ACS
TI The molecular mechanisms of chromosome abnormalities in T-cell leukemias and adult T-cell leukemias

=> D IBIB AB L21 9-14

L21 ANSWER 9 OF 14 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 95009211 EMBASE
DOCUMENT NUMBER: 1995009211
TITLE: Characterization and localization of the **TCL-1** oncogene product.
AUTHOR: Fu T.-B.; Virgilio L.; Narducci M.G.; Facchiano A.; Russo G.; Croce C.M.
CORPORATE SOURCE: Jefferson Cancer Institute, Jefferson Cancer Center, Jefferson Medical College, Philadelphia, PA 19107, United States
SOURCE: Cancer Research, (1994) 54/24 (6297-6301).
ISSN: 0008-5472 CODEN: CNREA8
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
025 Hematology
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The **TCL-1** gene maps at chromosome 14q32.1 and is activated in T cell leukemias and lymphomas by either chromosome translocations or inversions that juxtapose the **TCL-1** gene to the .alpha./.delta. or the .beta. locus of the T cell receptor. The open reading frame of the **TCL-1** gene, coding for a protein of 114 amino acids, was expressed in bacteria and antisera were raised against it, The antibodies recognized the predicted **TCL-1** M(r) 14,000 protein product in cells expressing **TCL-1** mRNA. Cell fractionation experiments indicated that the **TCL-1** protein is present in the microsomal fraction. These results were confirmed by confocal microscopy. The **TCL-1** protein has considerable sequence similarities to the product of the MTCP-1 gene on chromosome Xq28, which is involved in T cell lymphoproliferative diseases. Thus, **TCL-1** may represent a member of a novel family of genes involved in lymphoid proliferation and/or survival and in T cell malignancies.

L21 ANSWER 10 OF 14 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1999:297260 BIOSIS
DOCUMENT NUMBER: PREV199900297260
TITLE: Identification of the TCL1/MTCP1-like 1 (TML1) gene from the region next to the TCL1 locus.
AUTHOR(S): Sugimoto, Jun; Hatakeyama, Toyomasa; Narducci, Maria Grazia; Russo, Giandomenico; Isobe, Masaharu (1)
CORPORATE SOURCE: (1) Laboratory of Molecular and Cellular Biology, Department of Materials and Biosystem Engineering, Faculty of Engineering, Toyama University, 3190 Gofuku, Toyama City, 930-8555 Japan
SOURCE: Cancer Research, (May 15, 1999) Vol. 59, No. 10, pp. 2313-2317.
ISSN: 0008-5472.
DOCUMENT TYPE: Article
LANGUAGE: English

SUMMARY LANGUAGE: English

AB The region on chromosome 14q32.1 is frequently involved in chromosomal translocations and inversions with one of the T-cell receptor loci in human T-cell leukemias and lymphomas. The breakpoints of the different rearrangements segregate into two clusters: inversion on the centromeric side and simple balanced translocations on the telomeric side. If the target gene activated by these different types of chromosomal rearrangements is the same, the gene must reside between the two clusters of breakpoints in a region of apprx160 kb. By screening of a placenta cDNA library using genomic probes derived from the vicinity of TCL1 locus, we have identified a gene coding for a 1.7-kb transcript that is expressed in leukemic cells carrying a t(14;14)(q11;q32) chromosome translocation. The cognate cDNA sequence reveals an open reading frame of 384 nucleotides encoding a Mr 15,000 protein with apprx30% of homology with both p14TCL1 and p13MTCP1 oncoproteins. The genomic organization of the TML1 locus was characterized, with three exons located 15 kb from and tail-to-tail in relation to TCL1 locus. Because of its location and sequence similarity with TCL1 and MTCP1 oncoproteins, this gene, named TML1 (TCL1/MTCP1-like 1) is a candidate gene that is potentially involved in leukemogenesis.

L21 ANSWER 11 OF 14 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 1999:234743 BIOSIS
DOCUMENT NUMBER: PREV199900234743
TITLE: Role of TCL1 and ALL1 in human leukemias and development.
AUTHOR(S): Croce, Carlo M. (1)
CORPORATE SOURCE: (1) Kimmel Cancer Center, 233 South 10th Street, Room 1050, Philadelphia, PA, 19107 USA
SOURCE: Cancer Research, (April 1, 1999) Vol. 59, No. 7 SUPPL., pp. 1778s-1783s.
ISSN: 0008-5472.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

AB We have investigated the role of chromosomal translocations in the pathogenesis of human leukemias. The study of T-cell chronic lymphocytic leukemias and T-cell prolymphocytic **leukemia** has led to the identification of TCL1, a novel gene that is deregulated by translocations, t(14;14)(q11;q32), or inversions, inv(14)(q11; q32.1). Introduction of a human TCL1 gene juxtaposed to the lck promoter into fertilized mouse eggs resulted in the development of transgenic mice that developed mature T-cell leukemias, indicating that TCL1 is a transforming oncogene. We have also investigated acute leukemias with abnormalities at chromosome 11q23. We have identified a gene, ALL1, that can fuse to many different genes in acute leukemias. We have also shown that ALL1 can fuse with ALL1 in acute myelogenous **leukemia**. We have proposed that the ALL1 fusion genes may act by a dominant negative mechanism.

L21 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:418015 CAPLUS
DOCUMENT NUMBER: 125:83713
TITLE: Cloning of cDNA and gene of human **TCL-1** protein and use for diagnosis, prevention, and treatment of diseases
INVENTOR(S): Russo, Giandomenico; Croce, Carlo M.
PATENT ASSIGNEE(S): Thomas Jefferson University, USA; Raggio-Italgene, S.P.A.
SOURCE: PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613514	A1	19960509	WO 1995-US13663	19951023
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5985598	A	19991116	US 1994-330272	19941027
AU 9540084	A1	19960523	AU 1995-40084	19951023
PRIORITY APPLN. INFO.:			US 1994-330272	19941027
			WO 1995-US13663	19951023

AB The present invention relates to nucleotide sequences of **TCL-1** genes and amino acid sequences of their encoded proteins, as well as derivs. and analogs thereof, and antibodies thereto. The **TCL-1** gene sequence is preferentially expressed early in T and B lymphocyte differentiation and is mapped on chromosome 14q32.1.

A

PCR-based method using the nucleotides derived from **TCL-1** gene for detecting the chromosome 14 abnormality such as t(14;14)(q11;q32) translocation or an inv(14)(q11;q32) inversion is described. The present invention further relates to the use of **TCL-1** genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states assocd. with chromosomal abnormalities.

L21 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1996:229781 CAPLUS
DOCUMENT NUMBER: 124:285662
TITLE: MAGE-1 gene is expressed in T-cell **leukemia**
AUTHOR(S): Shichijo, Shigeki; Sagawa, Kimitaka; Brasseur, Francis; Boon, Thierry; Itoh, Kyogo
CORPORATE SOURCE: School of Medicine, Kurume University, Kurume, 830, Japan
SOURCE: Int. J. Cancer (1996), 65(5), 709-10
CODEN: IJCNAW; ISSN: 0020-7136
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The MAGE-1 gene was expressed in 12/23 T-cell leukemias (**TCL**), 1/11 B-cell leukemias (BCL), and 0/17 myeloid-monocyte leukemias (MML). In comparison, MAGE-2 gene was expressed in 3/23 TCL, 0/11 BCL, and 0/17 MML; MAGE-3 gene was expressed in 2/23 TCL, 0/11 BCL, and 0/17 MML; MAGE-4 gene was expressed in none of the leukemias; and MAGE-6 gene was expressed in 2/23 TCL, 0/11 BCL, and 4/17 MML.

L21 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:252324 CAPLUS
DOCUMENT NUMBER: 118:252324
TITLE: The molecular mechanisms of chromosome abnormalities in T-cell leukemias and adult T-cell leukemias
AUTHOR(S): Isobe, Masaharu
CORPORATE SOURCE: Res. Inst. Wakan-yaku, Toyama Med. Pharm. Univ., Toyama, 930-01, Japan
SOURCE: Jikken Igaku (1993), 11(5), 514-20
CODEN: JIIGEF; ISSN: 0288-5514
DOCUMENT TYPE: Journal; General Review
LANGUAGE: Japanese

AB A review with 18 refs., on the chromosome translocation at 14q11 in adult T-cell **leukemia** (ATL), which is independent of T-cell receptor (TCR) J.alpha. gene and different from ataxia telangiectasia (AT). The translocation occurs during the process of deterioration. **tcl-1** Is identified at the translocation site in AT. The translocation occurred in T-cell **leukemia** neg. for human virus-1 (HTLV-1) is discussed.

=> D HIS

(FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001)

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001
L1 1 S TCL-1
L2 1 S TCL-1

FILE 'USPATFULL, CAPLUS' ENTERED AT 19:04:57 ON 11 JAN 2001
L3 1 S L2

FILE 'REGISTRY' ENTERED AT 19:06:13 ON 11 JAN 2001
L4 0 S AECPTLGEAVTD
L5 0 S MLLELLPD
L6 2 S AECPTLGEAVTD/SQSP

FILE 'CAPLUS, USPATFULL' ENTERED AT 19:08:57 ON 11 JAN 2001
L7 4 S L6
L8 4 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 19:10:22 ON 11 JAN 2001
L9 3 S L6
L10 3 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)
L11 2058 S (CROCE, C?)/IN,AU
L12 2131 S (RUSSO, G?)/IN,AU
L13 89 S L11 AND L12
L14 11 S L13 AND TCL-1
L15 9 DUPLICATE REMOVE L14 (2 DUPLICATES REMOVED)
L16 8 S L15 NOT L8
L17 82 S TCL-1
L18 0 S L16 NOT L16
L19 74 S L17 NOT L16
L20 40 DUPLICATE REMOVE L19 (34 DUPLICATES REMOVED)
L21 14 S L20 AND LEUKEMIA

=> S L20 NOT L21

L22 26 L20 NOT L21

=> D TI L22 1-26

L22 ANSWER 1 OF 26 MEDLINE
TI Abnormal rearrangement within the alpha/delta T-cell receptor locus in lymphomas from Atm-deficient mice.

L22 ANSWER 2 OF 26 MEDLINE
TI Influence of the denticity of ligand systems on the in vitro and in vivo behavior of (99m)Tc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules.

L22 ANSWER 3 OF 26 MEDLINE
TI In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

L22 ANSWER 4 OF 26 MEDLINE
TI Purification and characterization of recombinant forms of murine Tcl1 proteins.

L22 ANSWER 5 OF 26 MEDLINE
TI Comparative analysis of invertebrate Tc6 sequences that resemble the vertebrate V(D)J recombination signal sequences (RSS).

L22 ANSWER 6 OF 26 MEDLINE
TI An inhibitor of type-1 cyclo-oxygenase in tissues from human pregnancy.

L22 ANSWER 7 OF 26 MEDLINE

TI Purification and characterization of recombinant forms of **TCL-1** and MTCP-1 proteins.

L22 ANSWER 8 OF 26 MEDLINE
TI Partial characterization of an immortalized human trophoblast cell-line, **TCL-1**, which possesses a CSF-1 autocrine loop [see comments].

L22 ANSWER 9 OF 26 MEDLINE
TI Identification of a nonameric H-2Kk-restricted CD8+ cytotoxic T lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein.

L22 ANSWER 10 OF 26 MEDLINE
TI Coordinate secretion and functional synergism of T cell-associated serine proteinase-1 (MTSP-1) and endoglycosidase(s) of activated T cells.

L22 ANSWER 11 OF 26 MEDLINE
TI Chromosome 14: a breakpoint in non-Hodgkin's lymphomas.

L22 ANSWER 12 OF 26 MEDLINE
TI Pathways for chloride and sodium transport across toad skin.

L22 ANSWER 13 OF 26 EMBASE COPYRIGHT 2001 ELSEVIER SCI. B.V.
TI [Ataxia-telangiectasia: Clinical, epidermological and genetic studies]. ATAXIE-TELANGIECTASIE: ASPECTS CLINIQUES, EPIDEMIOLOGIQUES ET GENETIQUES.

L22 ANSWER 14 OF 26 BIOSIS COPYRIGHT 2001 BIOSIS
TI Autocrine regulation of the proliferation of a human placental cell-line: the role of insulin-like growth factors.

L22 ANSWER 15 OF 26 BIOSIS COPYRIGHT 2001 BIOSIS
TI CYCLIC NUCLEOTIDE METABOLISM IN DIFFERENTIATED AND UNDIFFERENTIATED EPITHELIAL THYROID CELLS IN CULTURE.

L22 ANSWER 16 OF 26 BIOSIS COPYRIGHT 2001 BIOSIS
TI INTERRELATIONSHIP BETWEEN CYCLIC AMP METABOLISM AND GROWTH OF THYROID CELLS IN CULTURE.

L22 ANSWER 17 OF 26 BIOSIS COPYRIGHT 2001 BIOSIS
TI IODINE-125 THYROTROPIN BINDING TO THE PLASMA MEMBRANES OF NORMAL AND TUMOR THYROID CELL LINES.

L22 ANSWER 18 OF 26 BIOSIS COPYRIGHT 2001 BIOSIS
TI GANGLIOSIDES AND THEIR CELL DENSITY DEPENDENT CHANGES IN CONTROL AND CHEMICALLY TRANSFORMED C-3H-10T-1-2 CELLS.

L22 ANSWER 19 OF 26 BIOSIS COPYRIGHT 2001 BIOSIS
TI SCANNING ELECTRON MICROSCOPY CHARACTERIZATION OF IN-VITRO CHEMICALLY TRANSFORMED CELLS.

L22 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI Research of chloride removal catalyst for liquid phase

L22 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI Expression of TCL1 oncogene in orbital B cell lymphoma

L22 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI Possible explanation for opposite responses of EVT and **TCL-1** cells to endogenous CSF-1. Reply to comments

L22 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI On the transitions between the crystalline, amorphous, and liquid phases of silicon and germanium, when their size decreases

L22 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI Electron spin resonance study on second-stage manganese dichloride-graphite intercalation compound

L22 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI Device of cathodoluminescence microscope and its application to sedimentary petrology

L22 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2001 ACS
TI Fluctuational character of the development of the phase transition in liquid helium

=> D IBIB AB L22 4,7

L22 ANSWER 4 OF 26 MEDLINE
ACCESSION NUMBER: 2000200242 MEDLINE
DOCUMENT NUMBER: 20200242
TITLE: Purification and characterization of recombinant forms of murine Tcl1 proteins.
AUTHOR: Du Bois G C; Song S P; Kulikovskaya I; Rothstein J L; Germann M W; Croce C M
CORPORATE SOURCE: Department of Microbiology, Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, USA..
G_Dubois@iac.jci.tju.edu
SOURCE: PROTEIN EXPRESSION AND PURIFICATION, (2000 Apr) 18 (3) 277-85.
Journal code: BJV. ISSN: 1046-5928.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200008
ENTRY WEEK: 20000802
AB The TCL1 gene, which is located on chromosome 14, plays a major role in human hematopoietic malignancies and encodes a 14-kDa protein whose function has not been determined. This gene is expressed in pre-B cells, in immature thymocytes, and, at low levels, in activated T cells but not in peripheral mature B cells and in normal cells. The Tcl1 protein is similar in its primary structure to a protein encoded by the mature T-cell proliferation gene (MTCP1). The MTCP1 gene is located on the X chromosome and has been shown to be involved in rare chromosomal translocations in T-cell proliferative diseases. The murine TCL1 gene resides on mouse chromosome 12 and is homologous to the human TCL1 and MTCP1 genes. Murine Tcl1 protein has 116 amino acid residues and shares 50% sequence identity with human Tcl1, while the human and mouse Mtcp1 are nearly identical, with conservative differences in only six residues. The TCL1 and MTCP1 genes appear to be members of a family of genes involved in lymphoid proliferation and T-cell malignancies. Our laboratory has undertaken the study of the Tcl1 and Mtcp1 proteins to determine the structure and the function of these related proteins. In the present report, we have produced, using a bacterial expression system, the purified murine Tcl1 protein and a mutant form of murine Tcl1 protein containing a cysteine to alanine mutation at amino acid position 85. The recombinant proteins were purified by chromatography on a Ni-NTA resin followed by reverse-phase FPLC using a buffer system at pH 7.9 and a polymer-based reverse-phase column. The murine Tcl1 recombinant protein displays limited solubility and forms disulfide-linked dimers and oligomers, while the mutant murine Tcl1 C86A protein has increased solubility and does not form higher order oligomers. The purified recombinant murine proteins were characterized by N-terminal sequence analysis, mass spectrometry, and circular dichroism spectroscopy. Initial results indicate that the mutant murine Tcl1 C86A protein is suitable for both NMR and X-ray crystallographic methods of

structure determination. Copyright 2000 Academic Press.

L22 ANSWER 7 OF 26 MEDLINE
ACCESSION NUMBER: 1998191883 MEDLINE
DOCUMENT NUMBER: 98191883
TITLE: Purification and characterization of recombinant forms of **TCL-1** and MTCP-1 proteins.
AUTHOR: Du Bois G C; Song S P; Kulikovskaya I; Virgilio L; Varnum J; Germann M W; Croce C M
CORPORATE SOURCE: Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
SOURCE: PROTEIN EXPRESSION AND PURIFICATION, (1998 Mar) 12 (2) 215-25.
Journal code: BJV. ISSN: 1046-5928.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199807
ENTRY WEEK: 19980705

AB The **TCL-1** gene which is located on chromosome 14 plays a major role in human hematopoeitic malignancies and encodes a 14-kDa protein whose function has not been determined. The **TCL-1** gene is expressed in pre-B cells, in immature thymocytes, and at low levels in activated T cells but not in peripheral mature B cells and in normal cells. The **TCL-1** protein is similar in its primary structure to a protein encoded by the mature T cell proliferation gene (MTCP-1). The MTCP-1 gene is located on the X chromosome and has been shown to be involved in rare chromosomal translocations in T cell proliferative diseases. The **TCL-1** and MTCP-1 genes appear to be members of a family of genes involved in lymphoid proliferation and T cell malignancies. Our laboratory has undertaken the study of the **TCL-1** and MTCP-1 proteins to determine the structure and the function of these related proteins. In the present report, we have produced, using a bacterial expression system, both purified **TCL-1** and MTCP-1 proteins in forms with and without a six His tag sequence. The recombinant proteins were purified by chromatography on a Ni-NTA resin followed by reverse-phase FPLC using a buffer system at pH 7.9 and a polymeric-based reverse-phase column. The MTCP-1 recombinant proteins display greater solubility, do not form disulfide linked dimers or oligomers, and elute at a lower isopropanol concentration than the corresponding **TCL-1** proteins. The purified recombinant **TCL-1** and MTCP-1 proteins have been characterized by N-terminal sequence analysis, time of flight mass spectrometry, and circular dichroism spectroscopy. Initial results have indicated that the MTCP-1 protein with the His tag removed is suitable for both NMR and X-ray crystallographic methods of structure determination.

=> D HIS

(FILE 'HOME' ENTERED AT 19:00:30 ON 11 JAN 2001)

FILE 'REGISTRY' ENTERED AT 19:00:41 ON 11 JAN 2001
L1 1 S TCL-1
L2 1 S TCL-1

FILE 'USPATFULL, CAPLUS' ENTERED AT 19:04:57 ON 11 JAN 2001
L3 1 S L2

FILE 'REGISTRY' ENTERED AT 19:06:13 ON 11 JAN 2001
L4 0 S AECPTLGEAVTD

L5 0 S MLLE[redacted]RD
L6 2 S AECP[redacted]EAVTD/SQSP

FILE 'CAPLUS, USPATFULL' ENTERED AT 19:08:57 ON 11 JAN 2001
L7 4 S L6
L8 4 DUPLICATE REMOVE L7 (0 DUPLICATES REMOVED)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 19:10:22 ON 11 JAN 2001
L9 3 S L6
L10 3 DUPLICATE REMOVE L9 (0 DUPLICATES REMOVED)
L11 2058 S (CROCE, C?)/IN,AU
L12 2131 S (RUSSO, G?)/IN,AU
L13 89 S L11 AND L12
L14 11 S L13 AND TCL-1
L15 9 DUPLICATE REMOVE L14 (2 DUPLICATES REMOVED)
L16 8 S L15 NOT L8
L17 82 S TCL-1
L18 0 S L16 NOT L16
L19 74 S L17 NOT L16
L20 40 DUPLICATE REMOVE L19 (34 DUPLICATES REMOVED)
L21 14 S L20 AND LEUKEMIA